Tolvaptan
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Tolvaptan是精氨酸加压素（AVP）V2受体的选择性口服活性抑制剂，Ki值为0.43 nM[1]。
Tolvaptan是一种非肽类（AVP）V2受体拮抗剂。它可以阻止AVP与V2受体结合。在表达人AVP受体亚型的HeLa细胞中进行体外结合测定，tolvaptan抑制V2和V1a受体，Ki值分别为0.43 nM和12.3 nM。V1B受体及其他30个受体或离子通道对tolvaptan不敏感，这表明tolvaptan是V2受体选择性的。Tolvaptan也抑制AVP诱导的cAMP的产生，IC50值为8 nM [1]。
在动物模型中，tolvaptan导致尿量和血清钠增加。在急性和慢性低钠血症大鼠模型中，tolvaptan增加血浆钠含量，并降低了死亡率[1]。
参考文献：?
[1] Miyazaki T, Fujiki H, Yamamura Y, et al. Tolvaptan, an Orally Active Vasopressin V2-Receptor Antagonist-Pharmacology and Clinical Trials. Cardiovascular drug reviews, 2007, 25(1): 1-13.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 448.94 |
| Cas No. | 150683-30-0 |
| Formula | C26H25ClN2O3 |
| Solubility | insoluble in H2O; ≥17.8 mg/mL in DMSO; ≥2.71 mg/mL in EtOH with gentle warming and ultrasonic |
| Chemical Name | N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide |
| SDF | Download SDF |
| Canonical SMILES | CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
质量控制和MSDS
- 批次:
化学结构
